​

Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NBIX Stock Forecast

Neurocrine Biosciences (NBIX) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $174.42, with a high of $198.00 and a low of $146.00. This represents a 29.67% increase from the last price of $134.51.

$115 $132 $149 $166 $183 $200 High: $198 Avg: $174.42 Low: $146 Last Closed Price: $134.51

NBIX Stock Rating

Neurocrine Biosciences stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (86.11%), 5 Hold (13.89%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 0 5 31 Strong Sell Sell Hold Buy Strong Buy

NBIX Price Target Upside V Benchmarks

TypeNameUpside
StockNeurocrine Biosciences29.67%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.29%

Price Target Trends

1M3M12M
# Anlaysts41622
Avg Price Target$177.50$175.25$173.55
Last Closing Price$134.51$134.51$134.51
Upside/Downside31.96%30.29%29.02%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 265193--27
Dec, 255193--27
Nov, 256183--27
Oct, 256173--26
Sep, 256173--26
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 23, 2026UBS$178.00$137.3729.58%32.33%
Jan 08, 2026Truist Financial$169.00$140.6220.18%25.64%
Jan 08, 2026Morgan Stanley$175.00$140.6224.45%30.10%
Jan 05, 2026Ashwani VermaUBS$188.00$137.1537.08%39.77%
Dec 17, 2025H.C. Wainwright$198.00$148.7433.12%47.20%
Dec 11, 2025Stifel Nicolaus$188.00$154.6821.54%39.77%
Dec 08, 2025RBC Capital$180.00$159.4312.90%33.82%
Oct 29, 2025Danielle BrillTruist Financial$172.00$139.9022.94%27.87%
Oct 29, 2025UBS$183.00$136.9833.60%36.05%
Oct 29, 2025RBC Capital$160.00$136.9816.81%18.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 05, 2026UBSBuyBuyhold
Dec 17, 2025H.C. WainwrightBuyBuyhold
Dec 17, 2025JefferiesBuyBuyhold
Dec 17, 2025BMO CapitalMarket PerformMarket Performhold
Dec 08, 2025RBC CapitalOutperformOutperformhold
Dec 05, 2025Cowen & Co.BuyBuyhold
Nov 28, 2025Canaccord GenuityBuyBuyhold
Oct 29, 2025UBSBuyBuyhold
Oct 29, 2025RBC CapitalOutperformOutperformhold
Oct 29, 2025BMO CapitalMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$1.61$2.56$3.40----
Avg Forecast$1.78$2.22$2.56$4.05$6.40$8.65$11.24$14.00
High Forecast$1.87$2.34$2.94$4.34$7.44$11.63$15.31$14.86
Low Forecast$1.66$2.05$1.72$3.74$4.77$6.06$7.52$12.83
Surprise %-46.63%-27.48%--16.05%----

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.13B$1.49B$1.89B$2.36B----
Avg Forecast$1.14B$1.48B$1.89B$2.36B$2.77B$3.24B$3.68B$4.19B
High Forecast$1.18B$1.55B$1.90B$2.37B$2.84B$3.26B$3.71B$4.38B
Low Forecast$1.08B$1.40B$1.77B$2.34B$2.58B$3.22B$3.65B$3.92B
Surprise %-0.35%0.29%-0.12%-0.11%----

Net Income Forecast

$-2B $-800M $-100M $600M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.60M$154.50M$249.70M$341.30M----
Avg Forecast$110.42M$4.14M$249.70M$385.90M$637.97M$898.75M$1.20B$1.41B
High Forecast$138.10M$25.12M$1.67B$438.60M$751.03M$1.18B$1.55B$1.50B
Low Forecast$82.73M$-16.85M$-1.17B$378.03M$482.22M$611.63M$759.47M$1.30B
Surprise %-18.85%3635.85%--11.56%----

NBIX Forecast FAQ

Is Neurocrine Biosciences stock a buy?

Neurocrine Biosciences stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurocrine Biosciences is a favorable investment for most analysts.

What is Neurocrine Biosciences's price target?

Neurocrine Biosciences's price target, set by 36 Wall Street analysts, averages $174.42 over the next 12 months. The price target range spans from $146 at the low end to $198 at the high end, suggesting a potential 29.67% change from the previous closing price of $134.51.

How does Neurocrine Biosciences stock forecast compare to its benchmarks?

Neurocrine Biosciences's stock forecast shows a 29.67% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (18.29%).

What is the breakdown of analyst ratings for Neurocrine Biosciences over the past three months?

  • January 2026: 18.52% Strong Buy, 70.37% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 18.52% Strong Buy, 70.37% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Neurocrine Biosciences’s EPS forecast?

Neurocrine Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $6.4, marking a 88.24% increase from the reported $3.4 in 2024. Estimates for the following years are $8.65 in 2026, $11.24 in 2027, and $14 in 2028.

What is Neurocrine Biosciences’s revenue forecast?

Neurocrine Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $2.77B, reflecting a 17.65% increase from the reported $2.36B in 2024. The forecast for 2026 is $3.24B, followed by $3.68B for 2027, and $4.19B for 2028.

What is Neurocrine Biosciences’s net income forecast?

Neurocrine Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $637.97M, representing an 86.92% increase from the reported $341.3M in 2024. Projections indicate $898.75M in 2026, $1.2B in 2027, and $1.41B in 2028.